WEDNESDAY, Sept. 3, 2014 (HealthDay News) -- Ultrathin strut, biodegradable polymer sirolimus-eluting stents are associated with a similar risk of target lesion failure to thin strut durable polymer everolimus-eluting stents, according to a study published online Sept. 1 in The Lancet. These finding were published to coincide with the annual European Society of Cardiology Congress, held from Aug. 30 to Sept. 3 in Barcelona, Spain.
Thomas Pilgrim, M.D., from the University Hospital in Bern, Switzerland, and colleagues randomly assigned (1:1) patients (aged ≥18 years) with chronic stable coronary artery disease or acute coronary syndromes undergoing percutaneous coronary intervention to treatment with either biodegradable polymer sirolimus-eluting stents (1,063 patients; 1,594 lesions) or durable polymer everolimus-eluting stents (1,056 patients, 1,545 lesions). Target lesion failure -- a composite of cardiac death, target vessel myocardial infarction, and clinically-indicated target lesion revascularization at 12 months -- was the primary end point.
The researchers found that target lesion failure with biodegradable polymer sirolimus-eluting stents (69 cases) was non-inferior to durable polymer everolimus-eluting stents (70 cases) at 12 months (P for non-inferiority < 0.0004). There were no significant differences in rates of definite stent thrombosis (rate ratio, 2.26; 95 percent confidence interval, 0.70 to 7.33; P = 0.16). In patients with ST-segment elevation myocardial infarction, the biodegradable polymer sirolimus-eluting stents were associated with improved outcome versus the durable polymer everolimus-eluting stents (rate ratio, 0.38; 95 percent confidence interval, 0.16 to 0.91; P = 0.024).
"In a patient population with minimum exclusion criteria and high adherence to dual antiplatelet therapy, biodegradable polymer sirolimus-eluting stents were non-inferior to durable polymer everolimus-eluting stents for the combined safety and efficacy outcome target lesion failure at 12 months," the authors write. "The noted benefit in the subgroup of patients with ST-segment elevation myocardial infarction needs further study."
Several authors disclosed financial ties to the pharmaceutical industry.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
More Information
